Breast Cancer

Study to evaluate paclitaxel plus encequidar with dostarlimab +/- carboplatin in patients with breast cancer.

Approximately 30% of women gain weight following chemotherapy for breast cancer, gut bacteria may be why.

FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.

An axillary lymph node dissection, which is the surgical removal of 10 to 20 lymph nodes from the breast, is a procedure conducted in up to 25% of women with breast cancer to disable symptoms of arm swelling.

Lipid-lowering medication may be an effective adjuvant cancer therapy.

Women diagnosed with cancer as adolescents or young adults can be especially vulnerable to the impact of the disease and its treatment on their ability to work.

The authors concluded that a single dose of targeted intraoperative radiotherapy should be an option accessible to health care providers and discussed with patients.

Study findings align with recent recommendations from the National Comprehensive Cancer Network for preventing febrile neutropenia in patients with early-stage breast cancer.

Patients should talk to their health care team about when to reschedule a postponed or cancelled screening appointment.

Lenvatinib (Lenvima) plus pembrolizumab (Keytruda) showed early antitumor activity and tolerability in previously treated triple-negative breast cancer patients with advanced solid tumors.

Trial shows that olaparib, a poly ADP ribose polymerase inhibitor that is the first cancer drug to target an inherited genetic fault, can be used successfully to treat prostate cancers with a weakness in the ability to repair damaged DNA.

Study shows the recurrence rate was within the expected range for breast cancer survivors receiving spironolactone and those who did not.

A new test may help direct treatments for patients with rare breast cancer mutations.

It may take cells in different stages of development to cause breast cancer to progress and spread, according to recent research published in eLife.

Figuring out how to target vulnerable cells in breast cancer tumors can help treat the disease more effectively.

In a phase 3 clinical trial, oral paclitaxel was found to be just as effective intravenous paclitaxel in metastatic breast cancer.

The current study found no link between personal use of permanent hair dye and the risk of most cancers or cancer-related mortality.

Oral chemotherapy may be an important option for patients during the COVID-19 pandemic, as it would allow them to receive treatment at home.

Women who typically have a better prognosis in the primary breast cancer setting experienced worse survival after a second primary breast cancer.

Targeted photodynamic therapy has garnered increasing attention… because of its ability to treat tumors without surgery, chemotherapy, or radiation.

A new medication for certain rare blood cancers has now become available through a limited distribution with AllianceRx Walgreens Prime.

Targeted radiotherapy amounted to fewer deaths over a 5-year follow-up period among patients with breast cancer.

Researchers have found that gene expression associated with aging was higher in young cancer survivors who are frail and in young patients with cancer following their treatment with chemotherapy.

In addition to clinical procedures, some support groups for patients with breast cancer were also canceled as a result of the COVID-19 pandemic.

Most women with breast cancer receive treatment post surgery, such as chemotherapy, hormone therapy, and radiation. Targeted therapy is useful against cancers that have spread to distant parts of the body.

An online survey found that 44% of breast cancer survivors had care delayed during the COVID-19 pandemic.

The new analysis of the 23-year follow-up results of the trial found that screening women between 40 and 49 years of age led to a substantial and significant 25% reduction in breast cancer mortality in the first 10 years.

Because triple-negative breast cancer does not express receptors involved in most breast cancers, the investigative therapy could offer a much-needed option.

Four new subtypes of cells within triple-negative breast cancer have been uncovered, containing promising new therapeutic targets for the disease.

In the United States, these findings would translate to more than 269,000 prevented breast cancer cases and nearly 44,000 prevented cases of ovarian cancer.